Alumis Looks To Stand Out From The TYK2 Crowd With Psoriasis Data
Company Announces Series C Raise
The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.
The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.